-
公开(公告)号:US11306150B2
公开(公告)日:2022-04-19
申请号:US16476814
申请日:2018-01-10
摘要: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号:US20190330364A1
公开(公告)日:2019-10-31
申请号:US16476814
申请日:2018-01-10
IPC分类号: C07K16/28
摘要: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号:US12091462B2
公开(公告)日:2024-09-17
申请号:US17258866
申请日:2019-07-10
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC分类号: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US20240228653A1
公开(公告)日:2024-07-11
申请号:US18543912
申请日:2023-12-18
CPC分类号: C07K16/2896 , A61K45/06 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2319/30 , C07K2319/32
摘要: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号:US20210017283A1
公开(公告)日:2021-01-21
申请号:US16982277
申请日:2019-03-19
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US20200055936A1
公开(公告)日:2020-02-20
申请号:US16493712
申请日:2018-03-13
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC分类号: C07K16/28
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US20240092907A1
公开(公告)日:2024-03-21
申请号:US18162991
申请日:2023-02-01
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC分类号: C07K16/28
CPC分类号: C07K16/2812 , C07K2317/34 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US11603406B2
公开(公告)日:2023-03-14
申请号:US16493712
申请日:2018-03-13
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC分类号: C07K16/28
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US20220298258A1
公开(公告)日:2022-09-22
申请号:US17695081
申请日:2022-03-15
IPC分类号: C07K16/28
摘要: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号:US20220073617A1
公开(公告)日:2022-03-10
申请号:US17258866
申请日:2019-07-10
发明人: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
摘要: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
-
-
-
-
-
-
-
-